Providing stock analysis for investors of the Canadian junior markets
Last week, Quebec became the first governing medical body in Canada to publicly fund medical psilocybin-assisted psychotherapy, with advocates hoping
Read more
Mind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this morning, pricing yet another financing
Read more
Phase 1 trials are officially underway for Bright Minds Biosciences (CSE: DRUG) and their lead product, referred to as BMB-101.
Read more
Mind Medicine (NEO: MMED) might be slightly more volatile over the next few sessions. The psychedelic firm late on Friday
Read more
Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to
Read more
20-year-old Jake Freeman just walked away with around $110 million from selling his 6.21% stake in meme-stock favorite Bed Bath
Read more
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial results for Q2 2022. The
Read more
An activist shareholder battle might be brewing at Mind Medicine (NEO: MMED). This morning, co-founder of the company Dr Scott
Read more
In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that it’s directors have approved a
Read more
Mind Medicine (NEO: MMED) last night announced that it will be conducting a financing. The company is looking to raise
Read more